Neoadjuvant ipilimumab-nivolumab superior to adjuvant nivolumab

被引：0
|
作者：
Sidaway, Peter
机构：
[1] Nature Reviews Clinical Oncology,
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2024年 / 21卷 / 08期
关键词：
D O I：
10.1038/s41571-024-00916-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：566 / 566
页数：1
相关论文
共 50 条
  • [41] Ipilimumab/nivolumab/pembrolizumabVarious toxicities
    Reactions Weekly, 2023, 1958 (1) : 289 - 289
  • [42] Ipilimumab/Nivolumab/PembrolizumabNeutropenia and pneumonitis
    Reactions Weekly, 2024, 2014 (1) : 344 - 344
  • [43] Ipilimumab/Nivolumab/PembrolizumabMultiple toxicities
    Reactions Weekly, 2024, 1991 (1) : 124 - 124
  • [44] Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
    Postow, Michael A.
    Chesney, Jason
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth
    McDermott, David
    Linette, Gerald P.
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv S.
    Shaheen, Montaser
    Ernstoff, Marc S.
    Minor, David
    Salama, April K.
    Taylor, Matthew
    Ott, Patrick A.
    Rollin, Linda M.
    Horak, Christine
    Gagnier, Paul
    Wolchok, Jedd D.
    Hodi, F. Stephen
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21): : 2006 - 2017
  • [45] A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
    Bouligny, Ian M.
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Daver, Naval
    Jabbour, Elias
    Valero, Yesid Alvarado
    Dinardo, Courtney D.
    Ravandi, Farhad
    Borthakur, Gautam
    Bose, Prithviraj
    Pemmaraju, Naveen
    Kornblau, Steven M.
    Kadia, Tapan M.
    Masarova, Lucia
    Takahashi, Koichi
    Andreeff, Michael
    Bazinet, Alexandre
    Yang, Hui
    Kanagal-Shamanna, Rashmi
    Hosing, Chitra
    Pierce, Sherry
    Meyer, Meghan Anne
    Huang, Xuelin
    Garcia-Manero, Guillermo
    BLOOD, 2024, 144 : 4601 - 4603
  • [46] Neoadjuvant therapy with ipilimumab and nivolumab for stage III malignant melanoma - a case report
    Hansen, I.
    Heidrich, I.
    Belz, S.
    Noebel, C.
    Geidel, G.
    Hildebrandt, L.
    Schneider, S. W.
    Gebhardt, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 87 - 88
  • [47] Neoadjuvant Nivolumab and Ipilimumab for Resectable Stage III Melanoma: The New Standard of Care?
    Miura, John T.
    Karakousis, Giorgos C.
    ANNALS OF SURGICAL ONCOLOGY, 2025, 32 (03) : 1394 - 1396
  • [48] The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
    Lucas, Minke W.
    Lijnsvelt, Judith
    Pulleman, Saskia
    Scolyer, Richard A.
    Menzies, Alexander M.
    Van Akkooi, Alexander Christopher Jonathan
    Van Houdt, Winan J.
    Shannon, Kerwin Frank
    Pennington, Thomas
    Suijkerbuijk, Karijn
    Kapiteijn, Ellen
    Van der Veldt, Astrid Aplonia Maria
    Carlino, Matteo S.
    Sandhu, Shahneen
    Gonzalez, Maria
    Klop, Charlotte L. Zuur W. Martin. C.
    Long, Georgina V.
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
    Weber, J.
    Glutsch, V.
    Geissinger, E.
    Haug, L.
    Lock, J. F.
    Schneider, F.
    Kneitz, H.
    Goebeler, M.
    Schilling, B.
    Gesierich, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (03) : 559 - 563
  • [50] A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma
    Pothuri, Vikram
    Herndon, John
    Ballentine, Samuel J.
    Lim, Kian-Huat
    Fields, Ryan C.
    ONCOLOGIST, 2021, 26 (09): : 722 - 726
12345